| RLA/N |
number of periods of voluntary immobility |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
18 |
263.2 |
null |
7.8 |
33.1 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
|
68370 |
114 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 4 |
456.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic b-wave ERG |
108641 |
3128 |
| RCS-p+/LavRrrc |
photopic B wave amplitude of ERG waveform |
GSK-812 (2 ul) then visible light stimulus (25 cd x s/m2) |
Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. |
cone electrophysiology trait |
not specified |
119 days
| 7 |
28.9 |
uV |
2.5 |
6.61 |
electroretinography |
cornea |
0.0 |
intravitrial injection |
98 |
days |
|
|
109740 |
3154 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
23.8 |
uV |
1.9 |
3.29 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2 |
scotopic a-wave ERG |
108746 |
3131 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
20.9 |
uV |
3.7 |
6.41 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108748 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
199.0 |
uV |
17.0 |
29.44 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108750 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
208.5 |
uV |
14.36 |
35.17 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108516 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
241.17 |
uV |
16.89 |
41.37 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108517 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
584.5 |
uV |
55.51 |
135.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108525 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
644.33 |
uV |
50.52 |
123.75 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108526 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
11.45 |
uV |
3.56 |
9.42 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108537 |
3123 |
| RCS/LavRrrc |
b-wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
eye electrophysiology trait |
both |
0 days
| 5 |
24.0 |
uV |
10.0 |
22.36 |
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic b-wave ERG |
108665 |
3128 |
| RCS/N |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
rod electrophysiology trait |
not specified |
62 days
| 6 |
61.0 |
uV |
19.6 |
48.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
60 |
days |
contralateral control eye |
scotopic b-wave amplitude ERG |
108683 |
3129 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
327.83 |
uV |
16.41 |
40.2 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108405 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
652.5 |
uV |
65.65 |
160.81 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108415 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
27.7 |
uV |
4.72 |
11.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108423 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
243.17 |
uV |
24.11 |
59.06 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108427 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
570.67 |
uV |
21.08 |
51.64 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108438 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
6.38 |
uV |
1.4 |
3.43 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108440 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
216.67 |
uV |
19.46 |
47.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108445 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
438.83 |
uV |
24.27 |
59.45 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108460 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
11.68 |
uV |
2.42 |
8.03 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108465 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
104.17 |
uV |
12.63 |
41.89 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108467 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
18.46 |
uV |
3.3 |
10.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108471 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
87.05 |
uV |
8.87 |
29.42 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108472 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
201.55 |
uV |
19.9 |
66.0 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108475 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
44.02 |
uV |
13.47 |
44.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108476 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
466.45 |
uV |
51.69 |
171.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108484 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
567.73 |
uV |
56.78 |
188.32 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108486 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
13.98 |
uV |
3.06 |
7.5 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108494 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
71.98 |
uV |
18.54 |
45.41 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108500 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
385.17 |
uV |
61.99 |
151.84 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108501 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
605.83 |
uV |
62.69 |
153.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108505 |
3123 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
387.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic b-wave ERG |
108646 |
3128 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
195.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic a-wave ERG |
108649 |
3128 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
491.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic b-wave ERG |
108653 |
3128 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
23.1 |
uV |
4.0 |
8.94 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic a-wave ERG |
108730 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
135.0 |
uV |
38.0 |
84.97 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108731 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
114.0 |
uV |
16.0 |
35.78 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic b-wave ERG |
108732 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
112.85 |
uV |
11.14 |
27.29 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108514 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
18.53 |
uV |
4.77 |
12.63 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108538 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
83.4 |
uV |
14.8 |
39.16 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108543 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
145.24 |
uV |
12.56 |
33.23 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108544 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
192.0 |
uV |
14.42 |
38.15 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108545 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
31.22 |
uV |
8.16 |
21.59 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108551 |
3123 |
| RLA/N |
number of entries into a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
18 |
3.17 |
null |
0.71 |
3.0 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
prompted |
68361 |
114 |
| RCS-p+/LavRrrc |
photopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) |
Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. |
cone electrophysiology trait |
not specified |
119 days
| 7 |
23.1 |
uV |
1.0 |
2.65 |
electroretinography |
cornea |
0.0 |
intravitrial injection |
98 |
days |
|
|
109739 |
3154 |
| RCS/N |
ERG oscillatory potential |
lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) |
Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. |
eye electrophysiology trait |
not specified |
60 days
| 3 |
67.6 |
uV |
16.69 |
28.9 |
electroretinography |
cornea |
0.0 |
lens puncture |
30 |
days |
|
scotopic ocillatory index ERG |
108568 |
3124 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
17.1 |
uV |
3.2 |
7.16 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108733 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
570.67 |
uV |
53.5 |
131.05 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108510 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
16.61 |
uV |
4.28 |
10.48 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108518 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
124.83 |
uV |
7.26 |
17.78 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108522 |
3123 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 4 |
338.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic b-wave ERG |
108640 |
3128 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 9 |
59.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
photopic b-wave ERG |
108650 |
3128 |
| RCS/N |
photopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled visible light condition (30 cd/m2) (for 0.1 hours) then visible light stimulus (10 cd x s/m2) and controlled visible light condition (30 cd/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
cone electrophysiology trait |
not specified |
242 days
| 4 |
30.0 |
uV |
5.5 |
11.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
240 |
days |
treated eye |
photopic b-wave amplitude ERG |
108685 |
3129 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
108.63 |
uV |
17.19 |
42.11 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108395 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
143.17 |
uV |
20.27 |
49.65 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108397 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
430.17 |
uV |
45.59 |
111.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108409 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
532.5 |
uV |
62.77 |
153.75 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108412 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
638.33 |
uV |
68.2 |
167.06 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108414 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
23.02 |
uV |
5.24 |
12.84 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108417 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
94.57 |
uV |
13.87 |
33.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108424 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
149.83 |
uV |
9.83 |
24.08 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108425 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
519.33 |
uV |
29.94 |
73.34 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108432 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
497.33 |
uV |
42.65 |
104.47 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108437 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
155.28 |
uV |
13.68 |
33.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108443 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
78.77 |
uV |
13.41 |
32.85 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108448 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
381.17 |
uV |
37.99 |
93.06 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108453 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
516.5 |
uV |
29.8 |
72.99 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108461 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
5.17 |
uV |
1.18 |
3.91 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108464 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
118.51 |
uV |
12.59 |
41.76 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108468 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
137.5 |
uV |
12.91 |
42.82 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108469 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
12.43 |
uV |
2.29 |
7.6 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108470 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
351.91 |
uV |
47.74 |
158.34 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108479 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
56.72 |
uV |
16.42 |
54.46 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108482 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
24.73 |
uV |
6.11 |
14.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108489 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
166.85 |
uV |
19.57 |
47.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108492 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
145.83 |
uV |
14.32 |
35.08 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108497 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
206.0 |
uV |
11.62 |
28.46 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108499 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
485.67 |
uV |
73.15 |
179.18 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108503 |
3123 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
154.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic a-wave ERG |
108648 |
3128 |
| RCS/N |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
rod electrophysiology trait |
not specified |
62 days
| 6 |
175.0 |
uV |
14.7 |
36.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
60 |
days |
treated eye |
scotopic a-wave amplitude ERG |
108680 |
3129 |
| RCS/N |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
rod electrophysiology trait |
not specified |
62 days
| 6 |
500.0 |
uV |
61.24 |
150.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
60 |
days |
treated eye |
scotopic b-wave amplitude ERG |
108682 |
3129 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
15.31 |
uV |
2.98 |
7.88 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108549 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
159.83 |
uV |
21.35 |
56.49 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108558 |
3123 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
77 days
| 4 |
45.89 |
uV |
3.23 |
6.45 |
electroretinography |
retina |
0.0 |
hPDLSC transplant |
56 |
days |
|
|
109860 |
3157 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
77 days
| 4 |
12.57 |
uV |
1.42 |
2.84 |
electroretinography |
retina |
0.0 |
untreated control |
56 |
days |
|
|
109861 |
3157 |
| RHA/N |
number of periods of voluntary immobility |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
19 |
86.6 |
null |
7.69 |
33.5 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
|
68369 |
114 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
455.17 |
uV |
35.54 |
87.05 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108535 |
3123 |
| RHA/N |
time to first movement outside a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
19 |
5.97 |
s |
0.3 |
1.3 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
following stimulus |
68363 |
114 |
| RCS/N |
ERG oscillatory potential |
lensotomy then controlled visible light exposure (for 0.2 hours) then visible light stimulus (100 cd x s/m2) |
Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. |
eye electrophysiology trait |
not specified |
60 days
| 3 |
33.1 |
uV |
2.19 |
3.8 |
electroretinography |
cornea |
0.0 |
lens puncture |
30 |
days |
|
photopic ocillatory index |
108570 |
3124 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
24.5 |
uV |
4.9 |
10.96 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
|
scotopic a-wave ERG |
108734 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
83.0 |
uV |
7.0 |
15.65 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108735 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
19.36 |
uV |
3.48 |
8.52 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108513 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
16.11 |
uV |
3.41 |
8.35 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108519 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
748.17 |
uV |
64.77 |
158.65 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108528 |
3123 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
397.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic b-wave ERG |
108652 |
3128 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
203.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic a-wave ERG |
108655 |
3128 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 9 |
70.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
contralateral control eye |
photopic b-wave ERG |
108657 |
3128 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
144.0 |
uV |
29.0 |
50.23 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108751 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
162.07 |
uV |
9.02 |
22.09 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108419 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
7.62 |
uV |
1.56 |
3.82 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108422 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
65.42 |
uV |
13.87 |
33.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108428 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
373.83 |
uV |
17.47 |
42.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108429 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
437.0 |
uV |
33.32 |
81.62 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108431 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
594.5 |
uV |
24.04 |
58.89 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108433 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
42.97 |
uV |
8.99 |
22.02 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108434 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
356.17 |
uV |
23.35 |
57.2 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108435 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
621.67 |
uV |
35.23 |
86.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108439 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
25.21 |
uV |
4.23 |
10.36 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108441 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
88.5 |
uV |
12.52 |
30.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108442 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
201.67 |
uV |
18.19 |
44.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108444 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
26.68 |
uV |
7.67 |
18.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108447 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
56.16 |
uV |
17.2 |
42.13 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108452 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
579.0 |
uV |
50.99 |
124.9 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108457 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
144.39 |
uV |
13.24 |
43.91 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108473 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
170.91 |
uV |
16.52 |
54.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
a-wave amplitude ERG |
108474 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
334.55 |
uV |
43.36 |
143.81 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108478 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
410.45 |
uV |
48.4 |
160.52 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108483 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
607.73 |
uV |
58.9 |
195.35 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108487 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
15.46 |
uV |
4.1 |
10.04 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108488 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
80.6 |
uV |
11.3 |
27.68 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108490 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
178.0 |
uV |
12.3 |
30.13 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108498 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
429.5 |
uV |
66.11 |
161.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108502 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
101.1 |
uV |
20.75 |
50.83 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108506 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
393.0 |
uV |
65.49 |
160.42 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108507 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
533.17 |
uV |
67.99 |
166.54 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108508 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
587.17 |
uV |
49.54 |
121.35 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108509 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
8.81 |
uV |
1.84 |
4.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108392 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
25.3 |
uV |
2.85 |
6.98 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108399 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
161.92 |
uV |
30.48 |
74.66 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108401 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
224.32 |
uV |
34.64 |
84.85 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108403 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
371.67 |
uV |
28.82 |
70.59 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108406 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
391.5 |
uV |
33.43 |
81.89 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108407 |
3123 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 9 |
75.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
contralateral control eye |
photopic b-wave ERG |
108651 |
3128 |
| RCS/N |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.01 cd x s/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
rod electrophysiology trait |
not specified |
242 days
| 4 |
223.0 |
uV |
28.0 |
56.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
240 |
days |
treated eye |
scotopic b-wave amplitude ERG |
108684 |
3129 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
77 days
| 4 |
13.01 |
uV |
1.85 |
3.69 |
electroretinography |
retina |
0.0 |
pbs vehicle injection |
56 |
days |
|
|
109862 |
3157 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
49 days
| 4 |
13.93 |
uV |
1.49 |
2.98 |
electroretinography |
retina |
0.0 |
untreated control |
28 |
days |
|
|
109858 |
3157 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
49 days
| 4 |
29.44 |
uV |
7.44 |
14.87 |
electroretinography |
retina |
0.0 |
pbs vehicle injection |
28 |
days |
|
|
109859 |
3157 |
| RCS/N |
scotopic B wave amplitude of ERG waveform |
lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) |
Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. |
rod electrophysiology trait |
not specified |
60 days
| 3 |
30.5 |
uV |
7.51 |
13.0 |
electroretinography |
cornea |
0.0 |
lens puncture |
30 |
days |
|
scotopic b-wave ERG |
108567 |
3124 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
33.73 |
uV |
9.28 |
24.55 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108540 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
3.13 |
uV |
1.81 |
4.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108548 |
3123 |
| RCS/N |
photopic B wave amplitude of ERG waveform |
lensotomy then controlled visible light exposure (for 0.2 hours) then visible light stimulus (100 cd x s/m2) |
Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. |
cone electrophysiology trait |
not specified |
60 days
| 3 |
13.7 |
uV |
2.19 |
3.8 |
electroretinography |
cornea |
0.0 |
lens puncture |
30 |
days |
|
photopic b-wave ERG |
108569 |
3124 |
| RCS-p+/LavRrrc |
optokinetic reflex |
GSK-812 (2 ul) then visible light stimulus (25 cd x s/m2) |
Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. |
eye physiology trait |
not specified |
119 days
| 7 |
8.2 |
s |
0.4 |
1.06 |
optokinetic reflex test method |
|
60.0 |
intravitrial injection |
98 |
days |
|
|
109742 |
3154 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
29.7 |
uV |
11.3 |
25.27 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108729 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
231.0 |
uV |
5.0 |
8.66 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2 |
scotopic b-wave ERG |
108749 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
625.0 |
uV |
55.4 |
135.7 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
b wave amplitude ERG |
108511 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
16.12 |
uV |
3.84 |
9.41 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108512 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
89.88 |
uV |
11.06 |
27.09 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108521 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
138.93 |
uV |
9.28 |
22.73 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108523 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
119.08 |
uV |
22.02 |
53.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108524 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
739.67 |
uV |
44.42 |
108.81 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108527 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
354.0 |
uV |
16.81 |
41.18 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108531 |
3123 |
| RCS/LavRrrc |
b-wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
eye electrophysiology trait |
both |
0 days
| 5 |
137.0 |
uV |
18.0 |
40.25 |
electroretinography |
cornea |
0.0 |
subretinal injection |
60 |
days |
|
scotopic b-wave ERG |
108664 |
3128 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
352.0 |
uV |
26.0 |
58.14 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic b-wave ERG |
108701 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
186.0 |
uV |
23.8 |
53.22 |
electroretinography |
cornea |
0.0 |
|
37 |
days |
control for age matched plasmid injection |
scotopic b-wave ERG |
108702 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
114.0 |
uV |
16.1 |
36.0 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic b-wave ERG |
108703 |
3131 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
24.7 |
uV |
13.8 |
30.86 |
electroretinography |
cornea |
0.0 |
|
59 |
days |
control for age matched plasmid injection |
scotopic b-wave ERG |
108704 |
3131 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
96.3 |
uV |
10.3 |
23.03 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108725 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
15.03 |
uV |
4.72 |
11.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108393 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
118.43 |
uV |
17.52 |
42.92 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108396 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
190.68 |
uV |
32.08 |
78.58 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108402 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
51.68 |
uV |
12.61 |
30.89 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108404 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
62.22 |
uV |
18.42 |
45.12 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108410 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
592.83 |
uV |
68.9 |
168.77 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108413 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
95.25 |
uV |
7.15 |
17.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108418 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
240.67 |
uV |
14.84 |
36.35 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108421 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
202.33 |
uV |
17.65 |
43.23 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108426 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
382.17 |
uV |
30.52 |
74.76 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108430 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
399.83 |
uV |
37.74 |
92.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
b-wave amplitude ERG |
108436 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
514.67 |
uV |
47.85 |
117.21 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108455 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
587.83 |
uV |
53.2 |
130.31 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108456 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
49.97 |
uV |
12.07 |
29.57 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108458 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
358.5 |
uV |
35.71 |
87.47 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108459 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
584.5 |
uV |
38.15 |
93.45 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108462 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
598.67 |
uV |
39.64 |
97.1 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
b-wave amplitude ERG |
108463 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
71.37 |
uV |
8.23 |
27.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108466 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
270.09 |
uV |
34.35 |
113.93 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108477 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
389.91 |
uV |
52.11 |
172.83 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108480 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
518.55 |
uV |
54.69 |
181.39 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
pbs |
b wave amplitude ERG |
108485 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
188.33 |
uV |
15.56 |
38.11 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108493 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
30.66 |
uV |
9.93 |
24.32 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108495 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
100.23 |
uV |
12.78 |
31.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
pbs |
a wave amplitude ERG |
108496 |
3123 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 4 |
202.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic a-wave ERG |
108643 |
3128 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 4 |
51.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
photopic b-wave ERG |
108644 |
3128 |
| Hsd:SD |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
488.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
|
0 |
|
|
scotopic b-wave ERG |
108647 |
3128 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
49 days
| 4 |
204.9 |
uV |
52.13 |
104.26 |
electroretinography |
retina |
0.0 |
hPDLSC transplant |
28 |
days |
|
|
109857 |
3157 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
475.0 |
uV |
41.0 |
91.68 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108727 |
3131 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
5.86 |
uV |
0.76 |
2.01 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108536 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
7.44 |
uV |
1.43 |
3.78 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108542 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
24.79 |
uV |
7.82 |
20.69 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108552 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
10.28 |
uV |
1.69 |
4.47 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108554 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
32.75 |
uV |
13.42 |
35.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108555 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
94.13 |
uV |
15.33 |
40.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108556 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
131.7 |
uV |
16.13 |
42.68 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108557 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
179.49 |
uV |
20.75 |
54.9 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108559 |
3123 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
35 days
| 4 |
61.63 |
uV |
15.09 |
30.17 |
electroretinography |
retina |
0.0 |
untreated control |
14 |
days |
|
|
109855 |
3157 |
| N:HS |
number of entries into a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
20 |
2.6 |
null |
0.93 |
4.14 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
prompted |
68359 |
114 |
| N:HS |
time to first movement outside a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
20 |
14.32 |
s |
1.24 |
5.56 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
following stimulus |
68362 |
114 |
| RHA/N |
number of entries into a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
19 |
25.88 |
null |
1.26 |
5.5 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
prompted |
68360 |
114 |
| N:HS |
number of periods of voluntary immobility |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
20 |
257.49 |
null |
10.29 |
46.03 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
|
68368 |
114 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
110.0 |
uV |
14.0 |
31.3 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
|
scotopic b-wave ERG |
108736 |
3131 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 4 |
142.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic a-wave ERG |
108642 |
3128 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 9 |
57.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
photopic b-wave ERG |
108656 |
3128 |
| RCS-p+/LavRrrc |
optokinetic reflex |
vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) |
Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25. |
eye physiology trait |
not specified |
119 days
| 7 |
6.0 |
s |
0.27 |
0.71 |
optokinetic reflex test method |
|
60.0 |
intravitrial injection |
98 |
days |
|
|
109741 |
3154 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
60.2 |
uV |
8.5 |
19.01 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic a-wave ERG |
108726 |
3131 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
26.7 |
uV |
2.7 |
4.68 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108747 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
57.63 |
uV |
8.8 |
21.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
a-wave amplitude ERG |
108520 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
800.0 |
uV |
67.71 |
165.85 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
b-wave amplitude ERG |
108529 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
47.53 |
uV |
9.4 |
23.03 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108530 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
382.33 |
uV |
22.98 |
56.29 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108532 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
419.0 |
uV |
21.83 |
53.47 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108533 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
423.33 |
uV |
25.5 |
62.46 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + pbs |
b-wave amplitude ERG |
108534 |
3123 |
| Hsd:SD |
photopic B wave amplitude of ERG waveform |
controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
cone electrophysiology trait |
both |
0 days
| 4 |
90.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
contralateral control eye |
photopic b-wave ERG |
108645 |
3128 |
| Hsd:SD |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) |
Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. |
rod electrophysiology trait |
both |
0 days
| 9 |
173.0 |
uV |
|
|
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
days |
|
scotopic a-wave ERG |
108654 |
3128 |
| RCS/N |
scotopic A wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) |
Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. |
rod electrophysiology trait |
not specified |
62 days
| 6 |
16.0 |
uV |
6.94 |
17.0 |
electroretinography |
cornea |
0.0 |
AAV8 injection |
60 |
days |
contralateral control eye |
scotopic a-wave amplitude ERG |
108681 |
3129 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
78.43 |
uV |
13.51 |
33.09 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108394 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
9.73 |
uV |
2.39 |
5.85 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108398 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
109.52 |
uV |
22.74 |
55.7 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
a-wave amplitude ERG |
108400 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
411.83 |
uV |
43.52 |
106.6 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108408 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
460.67 |
uV |
47.48 |
116.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
7 |
days |
dl-aaa |
b-wave amplitude ERG |
108411 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
11.22 |
uV |
1.07 |
2.62 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108416 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
202.5 |
uV |
12.47 |
30.55 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
dl-aaa |
a-wave amplitude ERG |
108420 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
8.38 |
uV |
1.81 |
4.43 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108446 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
146.78 |
uV |
16.49 |
40.39 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108449 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
190.83 |
uV |
21.76 |
53.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108450 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
218.83 |
uV |
22.09 |
54.11 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
pbs |
a-wave amplitude ERG |
108451 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
440.0 |
uV |
43.67 |
106.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108454 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
410.09 |
uV |
45.37 |
150.48 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108481 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
119.33 |
uV |
19.43 |
47.59 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108491 |
3123 |
| RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
511.83 |
uV |
65.06 |
159.36 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108504 |
3123 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
35 days
| 4 |
143.41 |
uV |
12.18 |
24.35 |
electroretinography |
retina |
0.0 |
hPDLSC transplant |
14 |
days |
|
|
109854 |
3157 |
| RCS/LavRrrc |
scotopic B wave amplitude of ERG waveform |
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus |
Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. |
rod electrophysiology trait |
not specified |
35 days
| 4 |
95.22 |
uV |
16.19 |
32.38 |
electroretinography |
retina |
0.0 |
pbs vehicle injection |
14 |
days |
|
|
109856 |
3157 |
| RCS/N |
scotopic A wave amplitude of ERG waveform |
lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) |
Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. |
rod electrophysiology trait |
not specified |
60 days
| 3 |
18.3 |
uV |
4.79 |
8.3 |
electroretinography |
cornea |
0.0 |
lens puncture |
30 |
days |
|
scotopic a-wave ERG |
108566 |
3124 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
352.0 |
uV |
26.0 |
58.14 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic b-wave ERG |
108728 |
3131 |
| RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
172.6 |
uV |
20.12 |
49.28 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
dl-aaa + MPEP |
a-wave amplitude ERG |
108515 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
27.22 |
uV |
4.74 |
12.54 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108539 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
36.49 |
uV |
10.37 |
27.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108541 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
233.29 |
uV |
18.61 |
49.24 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108546 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
251.29 |
uV |
19.14 |
50.64 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108547 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
19.05 |
uV |
3.75 |
9.92 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108550 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
31.96 |
uV |
9.73 |
25.74 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108553 |
3123 |
| RLA/N |
time to first movement outside a discrete space in an experimental apparatus |
auditory stimulus (63 dB) (for 0 hours) and visible light stimulus (7 W) (for 0 hours) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
locomotor behavior trait |
both |
97 days-104 days |
18 |
15.93 |
s |
1.27 |
5.4 |
active avoidance test using a two-way shuttle box apparatus |
|
0.0 |
|
0 |
|
|
following stimulus |
68364 |
114 |
